CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 67 enrolled
Drug / intervention
ABT-494 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01741493
NCT01741493Phase 1Completed
CompareCT.gov

A Study in Healthy Adult Volunteers and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability, and Pharmacokinetics After Multiple Dosing of ABT-494

AbbVie (prior sponsor, Abbott)·interventional·Posted Dec 5, 2012·Updated Nov 20, 2017

In Brief

A Phase 1 clinical trial evaluating ABT-494, Placebo, and 1 other intervention for Rheumatoid Arthritis. Completed, enrolled 67 participants across 5 sites.

Detailed Summary

This is a phase 1, randomized, double-blind, placebo-controlled, multiple ascending dose study in healthy volunteers, multiple dose study in patients with rheumatoid arthritis and multiple dose study in healthy volunteers.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedDec 5, 2012
Enrollment StartNov 1, 2012
Primary CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 13.6 years ago

Interventions

ABT-494drug

Oral administration of ABT-494 capsules

Placebodrug

Oral administration of placebo capsules

Tofacitinibdrug

Oral administration